U.S. flag

An official website of the United States government

NM_001102469.2(LIPN):c.302del (p.Gly101fs) AND not specified

Germline classification:
Likely benign (1 submission)
Last evaluated:
Apr 7, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002235661.1

Allele description [Variation Report for NM_001102469.2(LIPN):c.302del (p.Gly101fs)]

NM_001102469.2(LIPN):c.302del (p.Gly101fs)

Gene:
LIPN:lipase family member N [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
10q23.31
Genomic location:
Preferred name:
NM_001102469.2(LIPN):c.302del (p.Gly101fs)
HGVS:
  • NC_000010.11:g.88764485del
  • NG_031911.1:g.8080del
  • NM_001102469.2:c.302delMANE SELECT
  • NP_001095939.1:p.Gly101fs
  • NC_000010.10:g.90524241del
  • NC_000010.10:g.90524242del
  • NM_001102469.1:c.302delG
Protein change:
G101fs
Links:
dbSNP: rs770938795
NCBI 1000 Genomes Browser:
rs770938795
Molecular consequence:
  • NM_001102469.2:c.302del - frameshift variant - [Sequence Ontology: SO:0001589]

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002511593Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Likely benign
(Apr 7, 2022)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Revisiting disease genes based on whole-exome sequencing in consanguineous populations.

Shamia A, Shaheen R, Sabbagh N, Almoisheer A, Halees A, Alkuraya FS.

Hum Genet. 2015 Sep;134(9):1029-34. doi: 10.1007/s00439-015-1580-3. Epub 2015 Jul 4.

PubMed [citation]
PMID:
26141664

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV002511593.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

Variant summary: LIPN c.302delG (p.Gly101GlufsX7) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay. The variant allele was found at a frequency of 0.00021 in 248456 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in LIPN causing Lamellar Ichthyosis (0.00021 vs 0.00025), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.302delG in individuals affected with Lamellar Ichthyosis and no experimental evidence demonstrating its impact on protein function have been reported. However, this variant has been found in three unaffected family members in homozygous state (Shamia_2015). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as likely benign. Based on the evidence outlined above, the variant was classified as likely benign.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024